stoxline Quote Chart Rank Option Currency Glossary
  
CytoMed Therapeutics Limited (GDTC)
2.09  0.05 (2.45%)    04-19 16:00
Open: 2.17
High: 2.17
Volume: 3,804
  
Pre. Close: 2.04
Low: 2.09
Market Cap: 24(M)
Technical analysis
2024-04-19 5:09:42 PM
Short term     
Mid term     
Targets 6-month :  2.75 1-year :  3.04
Resists First :  2.35 Second :  2.6
Pivot price 2.08
Supports First :  1.95 Second :  1.62
MAs MA(5) :  2.07 MA(20) :  2.1
MA(100) :  3.03 MA(250) :  3.32
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  31.6 D(3) :  27.4
RSI RSI(14): 45.6
52-week High :  9.25 Low :  1.91
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ GDTC ] has closed below upper band by 45.8%. Bollinger Bands are 79.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 32 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.18 - 2.19 2.19 - 2.19
Low: 2.06 - 2.08 2.08 - 2.09
Close: 2.07 - 2.09 2.09 - 2.11
Company Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

Headline News

Fri, 12 Apr 2024
CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 2.2% - Defense World

Mon, 18 Mar 2024
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies - Yahoo Finance

Mon, 04 Mar 2024
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to ... - Yahoo Finance

Mon, 04 Mar 2024
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to ... - GlobeNewswire

Wed, 07 Feb 2024
US Stocks Gain; Uber Posts Upbeat Sales - CytoMed Therapeutics (NASDAQ:GDTC), Glatfelter (NYSE:GLT) - Benzinga

Tue, 23 Jan 2024
GDTC Stock Price and Chart — NASDAQ:GDTC — TradingView - TradingView

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 12 (M)
Shares Float 2 (M)
Held by Insiders 70.7 (%)
Held by Institutions 0 (%)
Shares Short 35 (K)
Shares Short P.Month 19 (K)
Stock Financials
EPS -0.29
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 1.13
Profit Margin 0 %
Operating Margin -714.1 %
Return on Assets (ttm) -20.1 %
Return on Equity (ttm) -58.4 %
Qtrly Rev. Growth 281.2 %
Gross Profit (p.s.) 0
Sales Per Share 0.04
EBITDA (p.s.) -0.23
Qtrly Earnings Growth 0 %
Operating Cash Flow -3 (M)
Levered Free Cash Flow -2 (M)
Stock Valuations
PE Ratio -7.47
PEG Ratio 0
Price to Book value 1.83
Price to Sales 42.01
Price to Cash Flow -8.17
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android